Company: RCUS
Filing Date: 2025-10-31
Form Type: 424B5
Source: 0001193125-25-260836
Chunk: 48

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-31
Form: 424B5
Chunk 48
---
 clinical trials in certain timeframes; |

| • |     | our ability to develop intra-portfolio combinations and highly-differentiated small-molecule investigational                                          
 products, including our ability to create small-molecule investigational products with ideal pharmacological properties and desired clinical effects; |

| • |     | our expectations regarding the efficiency and speed with which we can create and advance small-molecule 
 investigational products and develop our investigational products and combination therapies;            |

| • |     | our reliance on third parties to conduct our ongoing and future clinical trials and third-party manufacturers to 
 manufacture and supply our investigational products;                                                             |

| • |     | our expectations regarding the nature of the immuno-oncology pathways we are targeting, the size of the potential 
 patient population and the potential market size;                                                                 |

| • |     | our ability to obtain and maintain control of our combination investigational products and maximize the 
 commercial potential of our investigational products;                                                   |

| • |     | our ability to obtain and maintain regulatory approvals of our investigational products and the potential market 
 opportunities for commercializing our investigational products;                                                  |

| • |     | our ability to retain and recruit key personnel, estimates of our expenses, future revenue, capital requirements 
 and our needs for additional financing;                                                                          |

| • |     | our ability to develop, acquire and advance investigational products into, and successfully complete, clinical 
 trials;                                                                                                        |

| • |     | our initiation, timing, progress and results of future research and development programs, preclinical studies and 
 clinical trials;                                                                                                  |

| • |     | our ability to obtain and maintain intellectual property rights covering our investigational products; |

| • |     | our expectations regarding the developments and projections relating to our competitors; |

| • |     | our expectations as to the effect that the COVID-19 pandemic will have on our company; and |

| • |     | our expectations regarding our industry. |

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We